For example, the combination of pembrolizumab (a PD-L1 inhibitor) plus entinostat (a histone deacetylase inhibitor) provides a clinically meaningful benefit to non-small cell lung cancer (NSCLC) patients who have shown resistance to PD-L1 inhibitors.18 The gene discussed is CD274; the disease is non-small cell lung carcinoma.